Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares (KNSA)
Kiniksa Pharmaceuticals International, plc (KNSA) is a biotechnology company focused on developing and commercializing therapies for immune-mediated and inflammatory diseases. Founded in 2015 and headquartered in Bermuda, the company leverages its platform to create innovative treatments aimed at addressing unmet medical needs, particularly in the fields of dermatology, rheumatology, and other immunology-related conditions.
Company News
Kiniksa Pharmaceuticals received FDA Orphan Drug Designation for KPL-387, a monoclonal antibody targeting pericarditis treatment, with potential for monthly subcutaneous self-injection.
The article highlights three healthcare stocks that are considered good investments right now: AbbVie, Vertex Pharmaceuticals, and Kiniksa Pharmaceuticals. It discusses the growth prospects and financial metrics of these companies.
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of -78.57% and 4.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Shares of Longboard Pharmaceuticals, Inc. (NASDAQ: LBPH) rose sharply during Tuesday’s session after the company released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs). Longboard Pharmaceuticals shares jumped 199....